(Q37185867)

English

Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial

scientific article published on 13 August 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 August 2017

Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial (English)

1 reference

Europe PubMed Central

18 August 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

adenoid cystic carcinoma

1 reference

based on heuristic

inferred from title

author name string

E Hitre

1

1 reference

Europe PubMed Central

18 August 2017

B Budai

2

1 reference

Europe PubMed Central

18 August 2017

Z Takácsi-Nagy

3

1 reference

Europe PubMed Central

18 August 2017

G Rubovszky

4

1 reference

Europe PubMed Central

18 August 2017

E Tóth

5

1 reference

Europe PubMed Central

18 August 2017

É Remenár

6

1 reference

Europe PubMed Central

18 August 2017

C Polgár

7

1 reference

Europe PubMed Central

18 August 2017

I Láng

8

1 reference

Europe PubMed Central

18 August 2017

language of work or name

0 references

publication date

13 August 2013

1 reference

Europe PubMed Central

18 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

18 August 2017

109

1 reference

Europe PubMed Central

18 August 2017

5

1 reference

Europe PubMed Central

18 August 2017

1117-1122

1 reference

Europe PubMed Central

18 August 2017

https://scigraph.springernature.com/pub.10.1038/bjc.2013.468

0 references

EGFR inhibition prevents in vitro tumor growth of salivary adenoid cystic carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778310

6 September 2017

Retracted: Epithelial Mesenchymal Transition Is Required for Acquisition of Anoikis Resistance and Metastatic Potential in Adenoid Cystic Carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778310

6 September 2017

Treatment outcomes and prognostic features in adenoid cystic carcinoma originated from the head and neck.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778310

6 September 2017

Concurrent chemoradiation for adenoid cystic carcinoma of the head and neck.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778310

6 September 2017

Combined treatment of adenoid cystic carcinoma with cetuximab and IMRT plus C12 heavy ion boost: ACCEPT [ACC, Erbitux® and particle therapy].

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778310

6 September 2017

A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778310

6 September 2017

Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778310

6 September 2017

Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778310

6 September 2017

RadioImmunotherapy for adenoid cystic carcinoma: a single-institution series of combined treatment with cetuximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778310

6 September 2017

Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778310

6 September 2017

Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778310

6 September 2017

Chemoradiotherapy for adenoid cystic carcinoma: preliminary results of an organ sparing approach

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778310

6 September 2017

A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778310

3 September 2018

Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778310

3 September 2018

Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778310

3 September 2018

Response to oxaliplatin with cetuximab in minor salivary gland adenoid cystic carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778310

3 September 2018

Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778310

3 September 2018

KRAS status and epidermal growth factor receptor expression as determinants for anti-EGFR therapies in salivary gland carcinomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778310

3 September 2018

Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778310

3 September 2018

Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778310

3 September 2018

Effects of imatinib mesylate on adenoid cystic carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778310

3 September 2018

Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778310

3 September 2018

Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: report of two successfully treated cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778310

3 September 2018

Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2013.468

21 January 2018

Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin

1 reference

https://pubmed.ncbi.nlm.nih.gov/23942070

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23942070

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm

1 reference

https://pubmed.ncbi.nlm.nih.gov/23942070

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands

1 reference

https://pubmed.ncbi.nlm.nih.gov/23942070

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors affecting the clinical outcome of adenoid cystic carcinoma of the head and neck

1 reference

https://pubmed.ncbi.nlm.nih.gov/23942070

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcomes and Prognostic Variables in Adenoid Cystic Carcinoma of the Head and Neck: A Recent Experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/23942070

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23942070

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23942070

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23942070

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Adenoid cystic carcinoma of the head and neck: a retrospective series of 169 cases]

1 reference

https://pubmed.ncbi.nlm.nih.gov/23942070

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metastatic adenoid cystic carcinoma of the salivary gland responding to cetuximab plus weekly paclitaxel after no response to weekly paclitaxel alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/23942070

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.2013.468

1 reference

Europe PubMed Central

18 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37185867&oldid=1693415256"